Tags

Type your tag names separated by a space and hit enter

Three-year update of sildenafil citrate (Viagra) efficacy and safety.
Int J Clin Pract. 2001 Mar; 55(2):115-28.IJ

Abstract

In the three years since its launch, sildenafil citrate (Viagra), an oral agent for the treatment of erectile dysfunction (ED), has been prescribed to more than 10 million patients worldwide and has been further evaluated in clinical studies in diverse patient populations. Significant improvements in erectile function have been demonstrated in double-blind, placebo-controlled trials in patients with ED and underlying diabetes, cardiovascular disease, minor depression, spinal cord injury and multiple sclerosis. Promising results have also been reported for patients with treated prostate cancer, end-stage renal failure, Parkinson's disease, and spina bifida and in multiple organ transplant recipients. Accounts of sildenafil use in clinical practice and postmarketing data reflect clinical trial findings of effectiveness in a broad spectrum of ED aetiologies and overall good tolerability. As in the clinical trials, most adverse events associated with sildenafil use have been transient, mild or moderate effects that rarely lead to treatment discontinuation.

Authors+Show Affiliations

Department of Family Practice, State University of New York Health Science Center, Box 67, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11321851

Citation

Sadovsky, R, et al. "Three-year Update of Sildenafil Citrate (Viagra) Efficacy and Safety." International Journal of Clinical Practice, vol. 55, no. 2, 2001, pp. 115-28.
Sadovsky R, Miller T, Moskowitz M, et al. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract. 2001;55(2):115-28.
Sadovsky, R., Miller, T., Moskowitz, M., & Hackett, G. (2001). Three-year update of sildenafil citrate (Viagra) efficacy and safety. International Journal of Clinical Practice, 55(2), 115-28.
Sadovsky R, et al. Three-year Update of Sildenafil Citrate (Viagra) Efficacy and Safety. Int J Clin Pract. 2001;55(2):115-28. PubMed PMID: 11321851.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Three-year update of sildenafil citrate (Viagra) efficacy and safety. AU - Sadovsky,R, AU - Miller,T, AU - Moskowitz,M, AU - Hackett,G, PY - 2001/4/27/pubmed PY - 2001/7/6/medline PY - 2001/4/27/entrez SP - 115 EP - 28 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 55 IS - 2 N2 - In the three years since its launch, sildenafil citrate (Viagra), an oral agent for the treatment of erectile dysfunction (ED), has been prescribed to more than 10 million patients worldwide and has been further evaluated in clinical studies in diverse patient populations. Significant improvements in erectile function have been demonstrated in double-blind, placebo-controlled trials in patients with ED and underlying diabetes, cardiovascular disease, minor depression, spinal cord injury and multiple sclerosis. Promising results have also been reported for patients with treated prostate cancer, end-stage renal failure, Parkinson's disease, and spina bifida and in multiple organ transplant recipients. Accounts of sildenafil use in clinical practice and postmarketing data reflect clinical trial findings of effectiveness in a broad spectrum of ED aetiologies and overall good tolerability. As in the clinical trials, most adverse events associated with sildenafil use have been transient, mild or moderate effects that rarely lead to treatment discontinuation. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/11321851/Three_year_update_of_sildenafil_citrate__Viagra__efficacy_and_safety_ L2 - https://medlineplus.gov/erectiledysfunction.html DB - PRIME DP - Unbound Medicine ER -